BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 38609996)

  • 1. Molecular characterization of diffuse large B-cell lymphomas associated with hepatitis C virus infection.
    Sciarra R; Merli M; Cristinelli C; Lucioni M; Zibellini S; Riboni R; Furlan D; Uccella S; Zerbi C; Bianchi B; Gotti M; Ferretti VV; Varraso C; Fraticelli S; Lazic T; Defrancesco I; Mora B; Libera L; Mazzacane A; Carpi F; Berliner M; Neri G; Rizzo E; De Paoli F; Sessa F; Passamonti F; Paulli M; Arcaini L
    Br J Haematol; 2024 Jun; 204(6):2242-2253. PubMed ID: 38442902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
    Xie Z; Qin Y; Chen X; Yang S; Yang J; Gui L; Liu P; He X; Zhou S; Zhang C; Tang L; Shi Y
    Target Oncol; 2024 May; 19(3):383-400. PubMed ID: 38643457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
    Østergaard S; Schejbel L; Breinholt MF; Pedersen MØ; Hammer T; Munksgaard L; Nørgaard P; Høgdall E; Gjerdrum LMR; Nielsen TH
    Leuk Lymphoma; 2024 Jun; 65(6):758-767. PubMed ID: 38340359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of CCND3 mutations in diffuse large B-cell lymphoma.
    Hua W; Li Y; Yin H; Du KX; Zhang XY; Wu JZ; Liang JH; Shen HR; Gao R; Li JY; Wang L; Liang JH; Xu W
    Ann Hematol; 2024 Jun; ():. PubMed ID: 38886191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrent Mutations in Refractory/Relapsed Diffuse Large B-Cell Lymphoma by Targeted Gene Sequencing.
    Sharma A; Das A; Bal A; Srinivasan R; Malhotra P; Prakash G; Kumar R
    Cytogenet Genome Res; 2023; 163(5-6):279-289. PubMed ID: 38071955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Molecular diagnostics for vitreoretinal lymphoma].
    Bonzheim I; Salmerón-Villalobos J; Süsskind D; Szurman P; Gekeler F; Spitzer MS; Salaverria I; Campo E; Coupland SE; Quintanilla-Martinez L; Fend F
    Pathologie (Heidelb); 2023 Dec; 44(Suppl 3):150-154. PubMed ID: 37947807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.
    Dobashi A
    J Clin Exp Hematop; 2016; 56(2):71-78. PubMed ID: 27980305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation landscape in Chinese nodal diffuse large B-cell lymphoma by targeted next generation sequencing and their relationship with clinicopathological characteristics.
    Cao B; Sun C; Bi R; Liu Z; Jia Y; Cui W; Sun M; Yu B; Li X; Zhou X
    BMC Med Genomics; 2024 Apr; 17(1):84. PubMed ID: 38609996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma.
    Shen R; Fu D; Dong L; Zhang MC; Shi Q; Shi ZY; Cheng S; Wang L; Xu PP; Zhao WL
    Signal Transduct Target Ther; 2023 Apr; 8(1):145. PubMed ID: 37032379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.
    Dubois S; Viailly PJ; Bohers E; Bertrand P; Ruminy P; Marchand V; Maingonnat C; Mareschal S; Picquenot JM; Penther D; Jais JP; Tesson B; Peyrouze P; Figeac M; Desmots F; Fest T; Haioun C; Lamy T; Copie-Bergman C; Fabiani B; Delarue R; Peyrade F; André M; Ketterer N; Leroy K; Salles G; Molina TJ; Tilly H; Jardin F
    Clin Cancer Res; 2017 May; 23(9):2232-2244. PubMed ID: 27923841
    [No Abstract]   [Full Text] [Related]  

  • 11. Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma.
    Xu-Monette ZY; Wei L; Fang X; Au Q; Nunns H; Nagy M; Tzankov A; Zhu F; Visco C; Bhagat G; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Hagemeister FB; Sun X; Han X; Go H; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Li Y; Xu B; Albitar M; You H; Young KH
    Clin Cancer Res; 2022 Mar; 28(5):972-983. PubMed ID: 34980601
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.
    Jiang S; Qin Y; Jiang H; Liu B; Shi J; Meng F; Liu P; Yang J; Yang S; He X; Zhou S; Gui L; Liu H; Lin J; Han-Zhang H; Shi Y
    Int J Cancer; 2020 Nov; 147(9):2611-2620. PubMed ID: 32399964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.
    Xie J; Shen X; Shi Q; Yi H; Ouyang B; Zhang Z; Gu Y; Dong L
    Hematol Oncol; 2022 Dec; 40(5):885-893. PubMed ID: 36053490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial.
    Zhang MC; Tian S; Fu D; Wang L; Cheng S; Yi HM; Jiang XF; Song Q; Zhao Y; He Y; Li JF; Mu RJ; Fang H; Yu H; Xiong H; Li B; Chen SJ; Xu PP; Zhao WL
    Cancer Cell; 2023 Oct; 41(10):1705-1716.e5. PubMed ID: 37774697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New agents and regimens for diffuse large B cell lymphoma.
    Wang L; Li LR; Young KH
    J Hematol Oncol; 2020 Dec; 13(1):175. PubMed ID: 33317571
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.